Table 8 LncRNAs as biomarkers for cardiovascular diseases
From: Expedition to the missing link: Long noncoding RNAs in cardiovascular diseases
| LncRNA | Clinical Application | Physiological/pathological impact | Mechanism involved |
|---|---|---|---|
| CoroMarker [132, 133] | Diagnosis of CAD | Decrease pro-inflammatory cytokine secretion from THP-1 monocytic cells | Unknown |
| LIPCAR [135] | Prediction of cardiac remodeling | Associated with future development of cardiac remodeling | Unknown |
| GAS5 [136,137,138] |
↑ in arterial plaques ↓ in plasma of CAD patients | Modulate macrophages and ECs apoptosis after ox-LDL stimulation | Unknown |
| SENCR [139,140,141] |
Diagnosis of early onset CAD: ↓ in circulating ECs ↑ in monocytes | Regulation of commitment from pluripotent cells and angiogenic capacity of EC | Regulate myocardin gene regulation to stabilize the contractile state of VSMCs |
| DKFZP434I0714 [144] | Prediction of adverse CV events in uremic patients | Modulate stress-induced EC apoptosis, endothelial dysfunction, and vascular inflammation | Unknown |